| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/24/2004 | WO2004052293A2 Recombinant vaccine against flavivirus infection |
| 06/24/2004 | WO2004052292A2 Histone deacetylase inhibitor enhancement of trail-induced apoptosis |
| 06/24/2004 | WO2004052289A2 Multilayered tablet containing pravastatin and aspirin |
| 06/24/2004 | WO2004052287A2 Topical composition for heightened sensitivity |
| 06/24/2004 | WO2004052285A2 Fat regulation |
| 06/24/2004 | WO2004052284A2 Treatment of diabetes |
| 06/24/2004 | WO2004052283A2 Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| 06/24/2004 | WO2004052280A2 Anti-angiogenic compounds and their use in cancer treatment |
| 06/24/2004 | WO2004052269A1 A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
| 06/24/2004 | WO2004052268A1 A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
| 06/24/2004 | WO2004052236A2 Methods and compositions for treatment of otitis media |
| 06/24/2004 | WO2004052227A2 Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| 06/24/2004 | WO2004052076A2 Mixed esters of dicarboxylic acids for use as pigment dispersants |
| 06/24/2004 | WO2004039320A3 STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF |
| 06/24/2004 | WO2004035020A3 Controlled release preparation |
| 06/24/2004 | WO2004032864A3 X-nitro compounds, pharmaceutical compositions thereof and uses therof |
| 06/24/2004 | WO2004030625A3 Synergistic methods and compositions for treating cancer |
| 06/24/2004 | WO2004028570A3 A method for treating severe tinnitus |
| 06/24/2004 | WO2004028469A3 Docohexaenoic acid for improved glycemic control |
| 06/24/2004 | WO2004026258A3 Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease |
| 06/24/2004 | WO2004026224A3 Process for preparing prostaglandin derivatives and starting materials for the same |
| 06/24/2004 | WO2004024896A3 Phenyl-indole compounds |
| 06/24/2004 | WO2004022716A3 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 06/24/2004 | WO2004022002A3 Combined immediate release and extended release analgesic composition |
| 06/24/2004 | WO2004020403A3 A composition and method to augment and sustain neurotransmitter production |
| 06/24/2004 | WO2004019873A9 Methods of promoting osteogenesis |
| 06/24/2004 | WO2004019869A3 Indoles having anti-diabetic activity |
| 06/24/2004 | WO2004019863A3 Combination therapy for treatment of fibrotic disorders |
| 06/24/2004 | WO2004018044A8 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 06/24/2004 | WO2004017922A3 Keto cannabinoids with therapeutic indications |
| 06/24/2004 | WO2004017903A3 Methods for treating fungal infections |
| 06/24/2004 | WO2004014309A3 Improved process for hydroxyazapirones |
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2004012684A3 M3muscarinic acetylcholine receptor antagonists |
| 06/24/2004 | WO2004011478A3 Anti-viral 7-deaza d-nucleosides and uses thereof |
| 06/24/2004 | WO2004011425A3 Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives |
| 06/24/2004 | WO2004010938A3 Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure |
| 06/24/2004 | WO2004006834A3 Leflunomide analogs for treating rheumatoid arthritis |
| 06/24/2004 | WO2003105864A9 Methods and compositions involving aldose reductase inhibitors |
| 06/24/2004 | WO2003105724A3 Novel maxi-k channel blockers, methods of use and process for making the same |
| 06/24/2004 | WO2003103699A8 Use of ramoplanin to treat diseases associated with the use of antibiotics |
| 06/24/2004 | WO2003103583A3 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 06/24/2004 | WO2003101389B1 Relief of aids symptoms |
| 06/24/2004 | WO2003099221A3 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 06/24/2004 | WO2003094839A8 Pyrimidinone compounds, compositions and methods |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 06/24/2004 | WO2003090690A3 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such |
| 06/24/2004 | WO2003075856A3 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
| 06/24/2004 | WO2003072056A3 Intranasal administration of mc4-r agonists |
| 06/24/2004 | WO2003064617A9 Pestalotiopsis microsporia isolates and compounds derived therefrom |
| 06/24/2004 | WO2003057200A3 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 06/24/2004 | WO2003053966A8 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 06/24/2004 | WO2003051841A3 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 06/24/2004 | WO2003049686A3 Stabilization of hypoxia inducible factor (hif) alpha |
| 06/24/2004 | WO2003047589A8 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 06/24/2004 | WO2003024386A8 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 06/24/2004 | WO2002092594A8 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 06/24/2004 | WO2002072021A3 Agents and methods for the prevention of initial onset and recurrence of existing cancers |
| 06/24/2004 | WO2002040056A9 Carrageenan viscoelastics for ocular surgery |
| 06/24/2004 | WO2002038141A3 Compositions and methods for treatment of mild cognitive impairment |
| 06/24/2004 | US20040122318 Tissue penetrating catheters having integral imaging transducers and their methods of use |
| 06/24/2004 | US20040122254 Selective cyclooxygenase-2(COX-2) inhibitors; free of gastrointestinal side effects; treating eye disorders such as glaucoma or selective cyclooxygenase-2(COX-2) inhibitors, rheumatoid arthritis, arthritis, pain, inflammation |
| 06/24/2004 | US20040122235 such as N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; for treating diseases in which increasing glucokinase activity is beneficial (diabetes) |
| 06/24/2004 | US20040122165 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 06/24/2004 | US20040122125 Lactone compounds as novel photoinitiators |
| 06/24/2004 | US20040122110 comprising topical administration of vitamin A for treating, healing, or regeneration of ciliated epithelial structures of mucosal membranes; used in the context of surgery, and post-surgical healing |
| 06/24/2004 | US20040122109 Preparation for hair and/or scalp |
| 06/24/2004 | US20040122108 Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions |
| 06/24/2004 | US20040122107 Method of alleviating barometric-induced symptoms in airline passengers |
| 06/24/2004 | US20040122105 Transdermal compositions |
| 06/24/2004 | US20040122104 has an enteric coating that delays the release of milnacipran within the stomach, thereby avoiding side effects such as nausea, vomiting, bleeding due to irritation of the gastric mucosa, sleep disturbance, headache etc |
| 06/24/2004 | US20040122103 humectant and skin barrier function reinforcing agent that improve the water retaining ability and barrier functions of the horny layer, are miscible and mixing stability |
| 06/24/2004 | US20040122102 compounds are potent ocular hypotensives, and are suitable for the management of glaucoma; they also are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases, gastrointestinal, reproduction disorders etc |
| 06/24/2004 | US20040122101 Polymorphs of suberoylanilide hydroxamic acid |
| 06/24/2004 | US20040122100 which contain EP1 agonist (which activate EP1 receptor that is subtype of prostaglandin E2 receptor) as an active ingredient |
| 06/24/2004 | US20040122097 Stimulation of in vivo production of proteins |
| 06/24/2004 | US20040122096 using guanidine derivatives, preferably acylguanidines as NHE inhibitors |
| 06/24/2004 | US20040122094 Isomers of conjugated linoleic acids at either the 1 and 3 or 2 positions of the acylglyceride molecule and another fatty acyl residue at the other of 1 and 3 OR 2 positions of acylglyceride molecule; useful as dietary supplements |
| 06/24/2004 | US20040122092 Hydroxyphenylundecane, a process for their production and their use |
| 06/24/2004 | US20040122090 capable of modulating the excitatory response of the neurons, inhibiting an excitotoxic effect, and promoting a neurotrophic effect, thereby providing a therapeutic effect that treats neuropsychiatric disorders |
| 06/24/2004 | US20040122089 Analogs of andandamide and arvanil have been found to act at receptors; are useful in pain management, used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications |
| 06/24/2004 | US20040122088 Zinc-monocysteine complex and method of using zinc-cysteine complexes |
| 06/24/2004 | US20040122087 Comprising 21-40 wt-% urea, and trace amounts of salts of zinc, copper and manganese and the balance an excipient; treating, protecting and re-epitheliazing skin disorders; wound healing agents; semisolids; moisture; microbiocides |
| 06/24/2004 | US20040122086 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 06/24/2004 | US20040122085 Compounds based on 1-oxoisochroman or - phthalan such as phyllodulcin and hydrangenol; food, beverage and feed additives; alcohol abuse |
| 06/24/2004 | US20040122084 7-Methyl-3.6,10,15-tetraoxapentacyclo [12.2.1.02,4. 05,7. 09,13]heptadec-1(17)-ene-11,16-dione derivatives; antitumor, -proliferative, -carcinogenic agents; viricides;DNA polymerase inhibitors; bactericides; solubility; stability; injections |
| 06/24/2004 | US20040122083 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin" |
| 06/24/2004 | US20040122082 A drug, a food, a beverage or a feed, each having an effective ingredient of a coumarin and/or a chroman compound having an enhancing action for nerve growth factors (NGF) production; nervous system disorders; Alzheimer's disease; plant extracts |
| 06/24/2004 | US20040122081 Intravenous formulation for a taxoid antitumor agent as a two-vial kit with the taxoid, solvent and buffer in one vial and cosolvent and buffer in the other; mixing prior to administration; improved solubility, stability and oxidation resistance |
| 06/24/2004 | US20040122080 Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
| 06/24/2004 | US20040122079 (R)-thiophene-2,5-dicarboxylic acid 2-hydroxyamide 5-[(1-thiophen-2-yl-ethyl)-amide], e.g.: antiproliferative agents; anticarcinogenic agents; enzyme inhibitors of histonedeacetylases; colon, breast, lung, prostate, rectal, stomach, bladder cancers |
| 06/24/2004 | US20040122078 A compound having slowly-deactivating A-type K+ channel opening activity such as N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide |
| 06/24/2004 | US20040122077 Administering a statin drug in an amount to promote angiogenesis in the tissue, preferably in situations where the subject is not otherwise in need of the drug ; activating Akt (protein kinase B) in vascular endothelial cells in vitro and in vivo |
| 06/24/2004 | US20040122076 The use of 1-(iso)indolylsulfonamido-),4-(alkylamido-)benzenes and derivatives as 5-Ht6receptor antagonists; Alzheimer's disease; neurodegenerative diseases; prophylaxis |
| 06/24/2004 | US20040122071 Fluconazole, a compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol and a base; favorable absorption and delivery through the human skin; low skin stimulation; stability; spreading |
| 06/24/2004 | US20040122068 Pramipexole and salts, e.g. dichloride, for use in the prevention and/or treatment of HIV-associated encephalopathy; motor disorders, cognitive impairment and behavioural disorders;.brain disorders; cognition activators |
| 06/24/2004 | US20040122067 Treatment of chronic heart failure |
| 06/24/2004 | US20040122066 Oxadiazole derivatives having anticancer effects |
| 06/24/2004 | US20040122065 Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally |
| 06/24/2004 | US20040122064 Enzyme inhibitors of both wild type and mutant variants of HIV reverse transcriptase, particularly resistant varieties; e.g.,N-{4-[(acetylamino)sulfonyl]-2-methylphenyl}-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide |